STOCK TITAN

Erasca to Present at the Morgan Stanley Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced its participation in the Morgan Stanley Global Healthcare Conference. On September 14, 2022, at 12:55 PM ET, CEO Jonathan E. Lim, M.D., and CFO David M. Chacko, M.D., will engage in a fireside chat at Sheraton Hotel, New York. They will also conduct one-on-one investor meetings. A live webcast will be available, with an archived replay accessible until December 14, 2022. Erasca is focused on therapies for RAS/MAPK pathway-driven cancers, aiming to develop innovative cancer treatments.

Positive
  • None.
Negative
  • None.

SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley Global Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a fireside chat at 12:55 pm Eastern Time on Wednesday, September 14, 2022, at the Sheraton Hotel in New York, New York. Drs. Lim and Chacko will also participate in one-on-one investor meetings.

A live webcast of the event will be available online at https://cc.webcasts.com. An archived replay of the event will be available until December 14, 2022, following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.


FAQ

What is the purpose of Erasca's participation in the Morgan Stanley Global Healthcare Conference?

Erasca aims to discuss its precision oncology efforts and engage with investors.

When will Erasca participate in the Morgan Stanley Global Healthcare Conference?

Erasca will participate on September 14, 2022, at 12:55 PM ET.

Who will represent Erasca at the Morgan Stanley Global Healthcare Conference?

CEO Jonathan E. Lim and CFO David M. Chacko will represent Erasca.

Where is the Morgan Stanley Global Healthcare Conference being held?

The conference is taking place at the Sheraton Hotel in New York, New York.

How can I watch Erasca's presentation at the conference?

A live webcast of the event will be available, and an archived replay can be accessed until December 14, 2022.

Erasca, Inc.

NASDAQ:ERAS

ERAS Rankings

ERAS Latest News

ERAS Stock Data

718.13M
228.31M
12.39%
87.01%
11.67%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO